A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly

Journal of Thoracic Oncology

Volumn 2, Issue 3, 2007, Pages 230-236

  Leong, Swan Swan ^a   Toh, Chee Keong ^a   Lim, Wan Teck ^a   Lin, Xu ^a   Tan, Say Beng ^a   Poon, Donald ^a   Tay, Miah Hiang ^a   Foo, Kian Fong ^a   Ho, Juliana ^a   Tan, Eng Huat ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; NAVELBINE; ONDANSETRON; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE REACTION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGE; CANCER STAGING; HEALTH STATUS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TAXOIDS; VINBLASTINE;

EID: 34247154396     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318031d06f     Document Type: Article

References (25)

1. Grilli R, Oxman AD, Julian JM. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-1872.
2. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
3. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-865.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
5. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
6. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
7. Altavilla G, Adamo V, Buemi B, et al. Gemcitabine as single agent in the treatment of elderly patients with advanced non-small cell lung cancer. Anticancer Res 2000;20:3675-3678.
8. Hainsworth JD, Burris 3rd HA, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network phase II trial. Cancer 2000;89:328-333.
9. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
10. Rocha Lima CM, Herndon 2nd JE, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002;94:181-187.
11. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
12. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194.
13. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
14. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC, 2002:93-114.
15. Toh CK, Lim WT, Leong SS, et al. Epidemiology of lung cancer in Singapore. Proceedings of WCLC. Lung Cancer 2005;49(suppl 2):S198-S313).
16. Hainsworth JD, Burris 3rd HA, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28(3 suppl 9):S21-S25.
17. Hirsh V, Latreille J, Kreisman H, et al. Sequential therapy with vinorelbine followed by gemcitabine in patients with metastatic non-small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities - a multicenter phase II trial. Lung Cancer 2005;49:117-123.
18. Marsland TA, Garfield DH, Khan MM, et al. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two phase II, multicenter trials. Lung Cancer 2005;47:111-120.
19. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. Br J Cancer 2000;83:447-453.
20. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657-3663.
21. Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006;32:583-587.
22. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529-2536.
23. Langer C, O'Byrne K, Ross H, et al. XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): the stellar 3 phase III study. Proceedings of WCLC. Lung Cancer 2005;49(suppl 2):S36-S101).
24. Stinchcombe TE, Socinski MA. Drug development in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004;31(suppl 11):S21-S26.
25. Baka S, Ashcroft L, Anderson H, et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status